Combined fluticasone propionate and salmeterol reduces RSV infection more effectively than either of them alone in allergen-sensitized mice
© Singam et al; licensee BioMed Central Ltd. 2006
Received: 15 February 2006
Accepted: 23 May 2006
Published: 23 May 2006
Respiratory syncytial virus (RSV) infection is the major cause of bronchiolitis in infants and is a risk factor for the development of asthma. Allergic asthmatics are more susceptible to RSV infection and viral exacerbation.
Since the effectiveness of corticosteroids in treating RSV infection has been controversial, we tested fluticasone propionate (FP) and salmeterol (Sal) alone versus FP plus Sal (FPS) on RSV-induced airway inflammation. Mice were sensitized and challenged with ovalbumin (OVA) and infected with RSV. Following infection they were treated with FP, Sal, or FPS intranasally and airway hyperreactivity (AHR), inflammation and RSV titers were examined.
The group treated with FPS showed significantly lower AHR compared to the group treated with FP or Sal alone. The group treated with FP alone showed slightly decreased (non-significant) AHR compared to controls. Treatment with FPS resulted in significant decreases in the percentage of eosinophils and neutrophils in bronchoalveolar lavage fluid and in lung pathology compared to FP or Sal. FP alone decreased eosinophils but not neutrophils or lymphocytes, while Sal alone decreased eosinophils and neutrophils but not lymphocytes. FPS treatment of mice infected with RSV in the absence of allergen sensitization resulted in a 50% decrease of RSV titer in the lung and a reduction in neutrophils compared to FP or Sal.
Together, these results indicate that fluticasone in combination with salmeterol is a more effective treatment for decreasing airway hyperreactivity and inflammation than either of them alone in allergen-sensitized, RSV-infected mice.
Asthma is a chronic lung disease with two distinct features – airway inflammation and airway hyperresponsiveness [1, 2]. An association between viral upper-respiratory infections (URIs) and exacerbations of asthma has been reported [3, 4]. The most commonly identified viruses in these studies include rhinovirus, coronavirus, influenza virus and respiratory syncytial virus (RSV) . RSV is the predominant cause of URIs in infants below 2 years of age and infection may result in bronchiolitis, which is a risk factor for asthma [6–12]. RSV may constitute the earliest trigger for the development of a T-helper type 2 (Th2)-dominant immune response, which is the hallmark of immunopathology in allergic subjects including asthmatics, and also in rodent models . URIs cause a decrease in peak flow that lags behind upper airway symptoms by 1–2 days, with 46% of subjects in one study reporting a two day lag in peak flow reduction .
A combination therapy involving a long-acting β2 agonist and an inhaled corticosteroid (ICS) has emerged as an effective asthma management strategy to control persistent asthma . A combination of salmeterol (Sal) and fluticasone propionate (FP) was found to be superior to either of them alone [16, 17]. The combination is also significantly more effective than montelukast plus FP or monotherapy with inhaled budesonide . The increased effectiveness of FPS has been attributed to increased activation and translocation to the nucleus of glucocorticoid receptors [19, 20]. However, the effect of these drugs on viral exacerbation in allergic asthmatics has not been studied.
The conclusion of the Cochrane Review of available controlled trials of ICS in children with a history of mild episodic viral wheeze was that high dose ICS was partially effective for the treatment of mild episodic viral wheeze of childhood . Since URIs induce exacerbations, β2-agonists may be of specific value in reducing such exacerbations. In an in vitro study of Pseudomonas aeruginosa infection, a combination of FP and Sal reduced infection and preserved ciliated cells to a greater degree than either alone suggesting synergy between the two agents . Because 80–85% of asthma exacerbations in children are associated with viral infections, early intervention with a combination therapy should have beneficial effects on viral asthma exacerbations.
Since virus-induced exacerbation is accompanied by airway inflammation, we reasoned that the combination of a steroid and a β-2 agonist might provide protection from severe RSV infection and the ensuing asthma exacerbation. This hypothesis was tested in a mouse model of allergen sensitization and RSV infection using OVA as the allergen . Mice with chronic or acute sensitization to OVA were RSV infected and then treated with FP or Sal or the two together (FPS). Airway hyperreactivity (AHR) and pulmonary inflammation were measured five days after infection. The results show that the combination of FP and Sal provides significant protection in terms of both airway hyperreactivity and pulmonary inflammation compared to either of them alone.
Female BALB/c mice, 4–6 weeks of age were obtained from Charles River and housed under pathogen-free conditions at the University of South Florida Vivarium. All treatment protocols were approved by the USF Institutional Animal Care and Use Committee (IACUC).
RSV preparation and infection of mice
The A2 strain of human RSV (American Type Culture Collection, Manassas, VA) was propagated in HEp-2 cells (American Type Culture Collection) grown in Eagle's minimal essential medium (Gibco) with 2% FBS. At maximum cytopathic effect, the cells were harvested in the same medium. The suspension was clarified by centrifugation at 700 × g for 10 min at 4°C and the resulting supernatant was layered onto a glycerol gradient and centrifuged at 14,000 × g for 3 hrs at 4°C. The pellet containing virus was resuspended in pre-cooled (4°C) buffer (0.22 μ-filtered 50 mM HEPES (pH 7.5), 100 mM MgSO4, and 150 mM NaCl) and stored in aliquots in liquid nitrogen. Viral titers were determined by standard plaque assay combined with immunostaining for RSV. Mice were infected under light anesthesia by intranasal inoculation of RSV (5 × 106 PFU).
OVA sensitization, RSV infection and drug treatment
For experiments in which only a single RSV infection was used (therapeutic regimen), mice were sensitized by intraperitoneal injection (i.p.) of OVA on day 1 and by intranasal (i.n.) administration of OVA on days 7 and 9. On day 9 the mice were infected i.n. with of RSV. From day 10 to day 13 they were treated daily i.n. with fluticasone (FP) propionate, salmeterol (Sal), or the two in combination (FPS) at 10 μg per mouse (FP and Sal were obtained from GlaxoSmithKline). Airway hyperreactivity (AHR) was measured on day 14 and on day 15 the animals were sacrificed. For the prophylactic experiments, mice were sensitized by intraperitoneal injection (i.p.) of OVA on day 1 and by intranasal (i.n.) administration of OVA on days 9, 12 and 14. On day 19 the mice were infected i.n. with of RSV. From day 21 to day 27 mice were treated daily i.n. with FP, Sal, or the two in combination (FPS) at 10 μg per mouse. On day 28, mice were reinfected with RSV and then challenged i.n. with OVA. AHR was measured on day 29. On day 30 the mice were sacrificed and BAL fluid, lungs and spleens were taken. All experiments were repeated at least twice.
Determination of airway hyperreactivity (AHR)
AHR, expressed as enhanced pause (Penh), was measured in unrestrained mice by whole body plethysmography (Buxco, Troy, NY). Groups of mice (n = 4) were exposed for 5 min to nebulized PBS to establish a baseline then to increasing concentrations (6–50 mg/ml) of nebulized methacholine (MCh; Sigma, St. Louis, MO) in PBS. Challenges were done for 5 min followed by recordings of Penh for 5 min. The Penh values were averaged and expressed for each MCh concentration as a percentage of the PBS baseline reading.
Bronchoalveolar lavage (BAL)
Lungs were lavaged using 500 μl of PBS and the BAL fluid was kept at 4°C until processed. BAL cells were centrifuged onto microscope slides by Cytospin (Shandon) and stained using the Hema3 kit (Fisher). Eosinophils, neutrophils and lymphocytes were counted from 5 different fields on 4 different slides from each group in a blinded fashion.
Lung sections were stained with hematoxylin and eosin (H&E) and inflammation was assessed as disruption or denudation of the epithelial layer and infiltration of monocytes and lymphocytes into the perialveolar region. Lung sections were also stained with antibodies to the cell-adhesion molecule ICAM-1, the goblet cell marker Muc-5A, and the Th2 marker T1/ST2 (Santa Cruz BioTech, Santa Cruz, CA).
Isolation of spleen cells and intracellular cytokine staining
Mice were sacrificed and single-cell suspensions were prepared from the spleens and cultured for 24 to 48 hrs in DMEM with 10% FBS. Splenocytes were incubated on anti-CD3-coated or OVA-coated plates for 24 h and then treated with Golgi-Stop for 4 hr to block the secretion of cytokines. Cells were surface-stained with FITC-anti-CD4 (Research Diagnostics, Flanders, NJ) and then subjected to intracellular staining with PE-anti-IFN-γ, -IL10 or -IL-4 antibodies (R&D Systems, Minneapolis, MN). Cells were analyzed by flow cytometry gated on CD4+ cells. The percentages of CD4+ cells secreting the respective cytokines are shown.
Measurement of cytokine levels in BAL cells
Mice were sacrificed and lungs were lavaged with PBS. Aliquots of the BAL fluid were stored at -80°C until assayed. The concentration of IFN-γ in the BAL was measured by ELISA using a kit (R&D Systems, Minneapolis, MN), and the results were expressed as pg of IFN-γ per ml of BAL fluid.
Lung sections were processed for detection of apoptosis using the DeadEnd™ Fluorometric TUNEL System assay kit (Promega). Dewaxed sections were fixed and permeablized, then incubated with terminal deoxynucleotidyl transferase to label DNA ends with FITC-dUTP. Stained sections were photographed under a fluorescent microscope.
All data were expressed as mean ± SEM. For comparison of two different groups, Student's t test was used. Differences between groups were considered significant at P < 0.05.
FPS is more effective than FP or Sal alone in preventing AHR and lung inflammation
FPS is more effective than FP alone in reducing viral exacerbation of asthma
Effect of FPS combination on cytokine and inflammatory marker expression
FPS inhibits apoptosis of lung cells
FPS decreases RSV titer and increases IFN-γ production
Our goal in this study was to determine if the combination of a corticosteroid and a long-acting β2-agonist was more effective in reducing RSV-induced asthma exacerbation than either drug alone. Here we demonstrate a reduction in lung inflammation in OVA-allergic mice infected with RSV after treatment with combined fluticasone and salmeterol. Eosinophil migration to the lung is characteristically seen during RSV-induced exacerbation of asthma , and both fluticasone and salmeterol reduced the eosinophil numbers in BAL fluid; but the combination of the two drugs was most effective. The basis of this synergy and whether the combination will be effective in infants and children affected by exposure to both viruses and allergens is unclear.
One important finding of this study is that irrespective of the frequency of RSV infection, the FPS combination therapy was effective and significantly decreased AHR as measured by % Penh. Also, in studies in which mice were infected twice with RSV, FPS decreased AHR more than FP alone. These results are in agreement with previous reports, where steroid or β2-agonists alone was found to be partially effective in RSV infection and viral induced asthma [24–26]. Consistent with the AHR data, there was a substantial reduction in pulmonary inflammation irrespective of the frequency of RSV infection. Of note is that in experiments where mice sensitized with OVA received one RSV infection, there was a decrease in eosinophils but an increase in lymphocytes. In contrast, OVA-sensitized mice that had two RSV infections before FP showed an increase in neutrophils. This is probably due to the resistance of neutrophils to corticosteroids and to the generation of a greater number of infiltrating neutrophils by the repeated RSV infection. The former possibility is consistent with the findings that neutrophilic asthma is resistant to treatment by FP . This suggests that addition of the long-acting beta agonist is the agent primarily affecting recruitment of neutrophils in the combination.
Furthermore, single versus double RSV infection induced significant differences in the expression of specific cytokines such as IL-10 and IL-4. RSV infection in BALB/c mice has been shown to increase a variety of cytokines and chemokines including TNF-α, IFN-γ, IL-6, IL-4, IL-10, RANTES, macrophage inflammatory protein-1 alpha, and eotaxin . Mice with a single infection showed an increased percentage of IL-10-producing cells perhaps indicative of greater stimulation of the innate immune system . Treatment with salmeterol alone resulted in a significantly higher percentage of IL-4-producing cells characteristic of the Th2-type response observed in human infants suffering from acute RSV bronchiolitis  while FPS decreased both IL-10 and IL-4. The numbers of cytokine-producing cells in splenocyte cultures are in agreement with the increased number of Th2-like cells seen in lung sections from salmeterol-treated mice. In mice infected twice with RSV, FPS reduced IL-10 but not IL-4 compared to FP or salmeterol alone-. This is consistent with our previous finding that allergic mice with two RSV infections had an increase in the number of cells producing IL-4 and IL-13 . Increased IL-10 production has been associated with recurrent wheezing in children hospitalized for RSV bronchiolitis [31, 32].
Another significant observation is the differential effect of FP and Sal on inflammatory markers. FP treatment caused an increase in ICAM-1 expression whereas Sal showed a small decrease. Treatment with the combination resulted in a decrease of ICAM-1 expression. This observation is consistent with previous reports which showed that FPS combination decreased ICAM-1 expression in human lung fibroblast cells [33, 34]. The expression of MUC-5A, which is a marker for mucus production, was also decreased by combined FPS treatment, but not significantly by either FP or Sal alone. Staining for the Th2-specific marker, T1/ST2 demonstrated the RSV-induced infiltration of Th2 cells. While treatment with FP increased ICAM-1 and MUC-5 expression, Th2 infiltration in lungs of FP-treated mice was decreased. In contrast, treatment with Sal did not inhibit Th2 infiltration. The combination FPS treatment decreased Th2 infiltration compared with Sal indicating that steroids and β2-agonists differentially affect inflammatory parameters, but that the two in combination can effectively reduce RSV-induced lung inflammation.
Apoptosis of lymphocytes in the lung is a characteristic feature of RSV bronchiolitis and may increase the severity of the disease . Our results indicated that compared to lungs of mice sensitized with OVA in the presence or absence of RSV infection, lungs of mice treated with either FP or Sal and the combination FPS showed a decreased number of apoptotic cells. The FPS combination shows even fewer apoptotic cells compared to FP or Sal alone suggesting the greater effectiveness of the combination treatment. The reason for this is unclear, but it may be due to the fact that treatment with FP or Sal decreases infiltration of inflammatory cells to the lungs. This idea is consistent with the report that FPS increases apoptosis of peripheral blood T cells .
Treatment with FP plus Sal decreases lung inflammation and examination of lung homogenates for RSV revealed a reduction in virus titer in the mice treated with FPS, suggesting that the combination treatment exerts additional antiviral effects. The measurement of IFN-γ in BAL fluid showed an increased production of IFN-γ in the lungs of mice treated with FPS therapy. Thus, the observed reduction in RSV titer may be due to increased IFN-γ levels in the lungs induced by the FPS combination therapy.
Although a number of experimental approaches are under investigation for the treatment of RSV infection [37–40], the possibility that such infection can be managed using already available therapies is an important finding. The results of this -study show that OVA-sensitized mice receiving fluticasone plus salmeterol had a significant reduction in RSV-induced inflammation and RSV titers compared to those receiving the drugs individually. Our results suggest that the use of a combination therapy can be very effective in reducing virally-induced asthma exacerbations.
fluticasone plus salmeterol
respiratory syncytial virus
T helper cell type 2
upper respiratory infection
SSM, RFL and DL designed the study and assisted in data evaluation and presentation. RS prepared RSV, performed infections, drug treatments, AHR measurements, and immunohistochemical analysis. PKJ performed OVA sensitization and RSV infection. SB obtained BAL fluid, isolated splenocytes and did cytokine assays. GRH performed apoptosis assays.
- Matsuse H, Behera AK, Kumar M, Lockey RF, Mohapatra SS: Differential cytokine mRNA expression in Dermatophagoides farinae allergen-sensitized and respiratory syncytial virus-infected mice. Microbes Infect 2000, 2: 753-759. 10.1016/S1286-4579(00)00500-1View ArticlePubMedGoogle Scholar
- Kay AB: Asthma and inflammation. J Allergy Clin Immunol 1991, 87: 893-910. 10.1016/0091-6749(91)90408-GView ArticlePubMedGoogle Scholar
- Gern JE, Busse WW: The role of viral infections in the natural history of asthma. J Allergy Clin Immunol 2000, 106: 201-212. 10.1067/mai.2000.108604View ArticlePubMedGoogle Scholar
- Minor TE, Dick EC, DeMeo AN, Ouellette JJ, Cohen M, Reed CE: Viruses as precipitants of asthmatic attacks in children. JAMA 1974, 227: 292-298. 10.1001/jama.227.3.292View ArticlePubMedGoogle Scholar
- Johnston SL, Pattemore PK, Sanderson G, Smith S, Campbell MJ, Josephs LK, Cunningham A, Robinson BS, Myint SH, Ward ME, Tyrrell DA, Holgate ST: The relationship between upper respiratory infections and hospital admissions for asthma: a time-trend analysis. Am J Respir Crit Care Med 1996, 154: 654-660.View ArticlePubMedGoogle Scholar
- Rooney JC, Williams HE: The relationship between proved viral bronchiolitis and subsequent wheezing. J Pediatr 1971, 79: 744-747. 10.1016/S0022-3476(71)80385-2View ArticlePubMedGoogle Scholar
- Gurwitz D, Mindorff C, Levison H: Increased incidence of bronchial reactivity in children with a history of bronchiolitis. J Pediatr 1981, 98: 551-555. 10.1016/S0022-3476(81)80758-5View ArticlePubMedGoogle Scholar
- Hall CB, Hall WJ, Gala CL, MaGill FB, Leddy JP: Long-term prospective study in children after respiratory syncytial virus infection. J Pediatr 1984, 105: 358-364. 10.1016/S0022-3476(84)80005-0View ArticlePubMedGoogle Scholar
- Mok JY, Simpson H: Symptoms, atopy, and bronchial reactivity after lower respiratory infection in infancy. Arch Dis Child 1984, 59: 299-305.PubMed CentralView ArticlePubMedGoogle Scholar
- Webb MS, Henry RL, Milner AD, Stokes GM, Swarbrick AS: Continuing respiratory problems three and a half years after acute viral bronchiolitis. Arch Dis Child 1985, 60: 1064-1067.PubMed CentralView ArticlePubMedGoogle Scholar
- Welliver RC, Duffy L: The relationship of RSV-specific immunoglobulin E antibody responses in infancy, recurrent wheezing, and pulmonary function at age 7–8 years. Pediatr Pulmonol 1993, 15: 19-27.View ArticlePubMedGoogle Scholar
- Sigurs N, Bjarnason R, Sigurbergsson F, Kjellman B, Bjorksten B: Asthma and immunoglobulin E antibodies after respiratory syncytial virus bronchiolitis: a prospective cohort study with matched controls. Pediatrics 1995, 95: 500-505.PubMedGoogle Scholar
- Graham BS, Bunton LA, Wright PF, Karzon DT: Reinfection of mice with respiratory syncytial virus. J Med Virol 1991, 34: 7-13.View ArticlePubMedGoogle Scholar
- Johnston SL, Pattemore PK, Sanderson G, Smith S, Lampe F, Josephs L, Symington P, O'Toole S, Myint SH, Tyrrell DA, Holgate ST: Community study of role of viral infections in exacerbations of asthma in 9–11 year old children. BMJ 1995, 310: 1225-1129.PubMed CentralView ArticlePubMedGoogle Scholar
- Wray BB: Asthma: best treatment options. Ann Allergy Asthma Immunol 2001, 87: 9-12.View ArticlePubMedGoogle Scholar
- Nelson HS: Combination therapy of bronchial asthma. Allergy Asthma Proc 2001, 22: 217-220.PubMedGoogle Scholar
- Barnes PJ: Scientific rationale for inhaled combination therapy with long-acting beta2-agonists and corticosteroids. Eur Respir J 2002, 19: 182-191. 10.1183/09031936.02.00283202View ArticlePubMedGoogle Scholar
- Lyseng-Williamson KA, Plosker GL: Inhaled salmeterol/fluticasone propionate combination: a pharmacoeconomic review of its use in the management of asthma. Pharmacoeconomics 2003, 21: 951-989. 10.2165/00019053-200321130-00004View ArticlePubMedGoogle Scholar
- Eickelberg O, Roth M, Lorx R, Bruce V, Rudiger J, Johnson M, Block LH: Ligand-independent activation of the glucocorticoid receptor by beta2-adrenergic receptor agonists in primary human lung fibroblasts and vascular smooth muscle cells. J Biol Chem 1999, 274: 1005-1010. 10.1074/jbc.274.2.1005View ArticlePubMedGoogle Scholar
- Goleva E, Dunlap A, Leung DY: Differential control of TH1 versus TH2 cell responses by the combination of low-dose steroids with beta2-adrenergic agonists. J Allergy Clin Immunol 2004, 114: 183-191. 10.1016/j.jaci.2004.04.001View ArticlePubMedGoogle Scholar
- McKean M, Ducharme F: Inhaled steroids for episodic viral wheeze of childhood. Cochrane Database Syst Rev 2000, CD001107.Google Scholar
- Dowling RB, Johnson M, Cole PJ, Wilson R: Effect of fluticasone propionate and salmeterol on Pseudomonas aeruginosa infection of the respiratory mucosa in vitro. Eur Respir J 1999, 14: 363-369. 10.1034/j.1399-3003.1999.14b21.xView ArticlePubMedGoogle Scholar
- Zhao J, Takamura M, Yamaoka A, Odajima Y, Iikura Y: Altered eosinophil levels as a result of viral infection in asthma exacerbation in childhood. Pediatr Allergy Immunol 2002, 13: 47-50. 10.1034/j.1399-3038.2002.00051.xView ArticlePubMedGoogle Scholar
- Noah TL, Wortman IA, Becker S: The effect of fluticasone propionate on respiratory syncytial virus-induced chemokine release by a human bronchial epithelial cell line. Immunopharmacology 1998, 39: 193-199. 10.1016/S0162-3109(98)00017-4View ArticlePubMedGoogle Scholar
- Panitch HB: Respiratory syncytial virus bronchiolitis: supportive care and therapies designed to overcome airway obstruction. Pediatr Infect Dis J 2003, 22: S83-87. 10.1097/00006454-200302001-00012PubMedGoogle Scholar
- Steiner RW: Treating acute bronchiolitis associated with RSV. Am Fam Physician 2004, 69: 325-330.PubMedGoogle Scholar
- Kabra SK, Lodha R: Management of unresponsive asthma. Indian J Pediatr 2004, 71: 729-732.View ArticlePubMedGoogle Scholar
- Jafri HS, Chavez-Bueno S, Mejias A, Gomez AM, Rios AM, Nassi SS, Yusuf M, Kapur P, Hardy RD, Hatfield J, Rogers BB, Krisher K, Ramilo O: Respiratory syncytial virus induces pneumonia, cytokine response, airway obstruction, and chronic inflammatory infiltrates associated with long-term airway hyperresponsiveness in mice. J Infect Dis 2004, 189: 1856-1865. 10.1086/386372View ArticlePubMedGoogle Scholar
- Krishnan S, Craven M, Welliver RC, Ahmad N, Halonen M: Differences in participation of innate and adaptive immunity to respiratory syncytial virus in adults and neonates. J Infect Dis 2003, 188: 433-439. 10.1086/376530View ArticlePubMedGoogle Scholar
- Legg JP, Hussain IR, Warner JA, Johnston SL, Warner JO: Type 1 and type 2 cytokine imbalance in acute respiratory syncytial virus bronchiolitis. Am J Respir Crit Care Med 2003, 168: 633-639. 10.1164/rccm.200210-1148OCView ArticlePubMedGoogle Scholar
- Bont L, Heijnen CJ, Kavelaars A, van Aalderen WM, Brus F, Draaisma JT, Geelen SM, Kimpen JL: Monocyte IL-10 production during respiratory syncytial virus bronchiolitis is associated with recurrent wheezing in a one-year follow-up study. Am J Respir Crit Care Med 2000, 161: 1518-1523.View ArticlePubMedGoogle Scholar
- Bont L, Aalderen WM, Kimpen JL: Long-term consequences of respiratory syncytial virus (RSV) bronchiolitis. Paediatr Respir Rev 2000, 1: 221-227. 10.1053/prrv.2000.0052PubMedGoogle Scholar
- Sabatini F, Silvestri M, Sale R, Serpero L, Giuliani M, Scarso L, Favini P, Rossi GA: Concentration-dependent effects of mometasone furoate and dexamethasone on foetal lung fibroblast functions involved in airway inflammation and remodeling. Pulm Pharmacol Ther 2003, 16: 287-297. 10.1016/S1094-5539(03)00068-3View ArticlePubMedGoogle Scholar
- Ek A, Larsson K, Siljerud S, Palmberg L: Fluticasone and budesonide inhibit cytokine release in human lung epithelial cells and alveolar macrophages. Allergy 1999, 54: 691-699. 10.1034/j.1398-9995.1999.00087.xView ArticlePubMedGoogle Scholar
- Roe MF, Bloxham DM, White DK, Ross-Russell RI, Tasker RT, O'Donnell DR: Lymphocyte apoptosis in acute respiratory syncytial virus bronchiolitis. Clin Exp Immunol 2004, 137: 139-145. 10.1111/j.1365-2249.2004.02512.xPubMed CentralView ArticlePubMedGoogle Scholar
- Pace E, Gagliardo R, Melis M, La Grutta S, Ferraro M, Siena L, Bonsignore G, Gjomarkaj M, Bousquet J, Vignola AM: Synergistic effects of fluticasone propionate and salmeterol on in vitro T-cell activation and apoptosis in asthma. J Allergy Clin Immunol 2004, 114: 1216-1223. 10.1016/j.jaci.2004.07.052View ArticlePubMedGoogle Scholar
- Kumar M, Behera A, Matsuse H, Lockey R, Mohapatra SS: Intranasal IFN-g transfer of prevents respiratory syncytial virus infection in BALB/c mice. Vaccine 1999, 18: 558-567. 10.1016/S0264-410X(99)00185-1View ArticlePubMedGoogle Scholar
- Kumar M, Behera AK, Lockey RF, Zhang J, Perez de la Cruz C, Chen l, Leong KW, Huang S-K, Mohapatra SS: Intranasal gene transfer by chitosan-DNA nanospheres protects BALB\C mice against acute respiratory syncytial virus infection. Human Gene Therapy 2002, 13: 1415-1425. 10.1089/10430340260185058View ArticlePubMedGoogle Scholar
- Kumar M, Kong X, Behera A, Hellermann G, Lockey RF, Mohapatra SS: Chitosan IFN-γ-pDNA Nanoparticle (CIN) Therapy for Allergic Asthma. Genetic Vaccines and Therapy 2003, 1: 3. 10.1186/1479-0556-1-3PubMed CentralView ArticlePubMedGoogle Scholar
- Zhang W, Yang H, Kong X, Mohapatra S, Juan-Vergara HS, Hellermann G, Behera S, Singam R, Lockey RF, Mohapatra SS: Inhibition of respiratory syncytial virus infection with intranasal siRNA nanoparticles targeting the viral NS1 gene. Nature Medicine 2005, 11: 56-62. 10.1038/nm1174View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.